tiprankstipranks
Trending News
More News >
Perseus Proteomics, Inc. (JP:4882)
:4882
Japanese Market
Advertisement

Perseus Proteomics, Inc. (4882) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4882

Perseus Proteomics, Inc.

(4882)

Rating:42Neutral
Price Target:
Perseus Proteomics, Inc. faces significant financial challenges marked by negative profitability and cash flow issues despite strong revenue growth. The technical indicators suggest downward momentum and possible oversold conditions, further weighing on the stock. Valuation is difficult due to negative earnings, resulting in a low overall stock score.

Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)

Perseus Proteomics, Inc. Business Overview & Revenue Model

Company DescriptionPerseus Proteomics, Inc. (4882) is a biotechnology company focused on the research and development of antibody-based therapeutics. The company operates in the life sciences sector, specializing in the discovery and commercialization of monoclonal antibodies for the treatment of various diseases. Its core products include therapeutic antibodies that target specific proteins involved in disease processes.
How the Company Makes MoneyPerseus Proteomics, Inc. generates revenue primarily through the development and commercialization of antibody-based therapeutics. The company's revenue streams include licensing agreements, collaborations with pharmaceutical and biotechnology companies, and sales of its developed products. Significant partnerships with larger pharmaceutical firms may provide upfront payments, milestone payments upon reaching certain development stages, and royalties from product sales. The company also invests in proprietary research to build a robust pipeline of potential therapies that can be licensed or sold, further contributing to its earnings.

Perseus Proteomics, Inc. Financial Statement Overview

Summary
Perseus Proteomics, Inc. shows strong revenue growth but struggles with profitability due to high operational losses. The balance sheet is robust with no debt, providing stability; however, ongoing cash flow challenges and operational inefficiencies are concerning despite a healthy cash reserve.
Income Statement
32
Negative
The company has shown a consistent increase in revenue over the years, with a TTM revenue of 111.4 million JPY. However, persistent negative EBIT and EBITDA margins indicate high operational costs and inefficiencies. Despite having a high gross profit margin of 85.4%, the net profit margin remains negative due to substantial losses. This significantly impacts the overall profitability and financial health of the company.
Balance Sheet
58
Neutral
The balance sheet shows a strong equity base with zero debt, resulting in a favorable debt-to-equity ratio of 0. The equity ratio is robust at 82.1%, indicating financial stability. Nevertheless, the company’s persistent net losses are concerning, as they negatively affect the return on equity, which is deeply in the negative territory.
Cash Flow
41
Neutral
The cash flow statement highlights a negative free cash flow, which has shown some improvement in the TTM. The operating cash flow is consistently negative, which raises concerns about the company's ability to sustain operations without external financing. Despite this, the company has a strong cash position, helping it to manage its operational needs.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue120.38M100.40M94.20M71.93M67.95M
Gross Profit104.05M87.69M86.53M67.75M64.10M
EBITDA-899.49M-892.00M-692.00M-471.00M-411.23M
Net Income-904.80M-1.10B-787.00M-599.02M-413.22M
Balance Sheet
Total Assets1.82B1.69B2.57B3.30B1.12B
Cash, Cash Equivalents and Short-Term Investments1.67B1.54B2.44B3.21B1.07B
Total Debt0.000.000.000.000.00
Total Liabilities386.43M295.46M170.10M148.38M34.91M
Stockholders Equity1.43B1.40B2.40B3.15B1.08B
Cash Flow
Free Cash Flow-794.64M-992.87M-734.82M-510.71M-425.66M
Operating Cash Flow-719.49M-833.90M-564.27M-476.84M-422.84M
Investing Cash Flow-75.16M-150.34M-212.99M-33.87M-2.82M
Financing Cash Flow923.38M63.94M-20.00K2.65B1.01B

Perseus Proteomics, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price410.00
Price Trends
50DMA
418.62
Negative
100DMA
480.54
Negative
200DMA
555.21
Negative
Market Momentum
MACD
-2.06
Positive
RSI
46.15
Neutral
STOCH
30.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 410 is below the 20-day moving average (MA) of 412.75, below the 50-day MA of 418.62, and below the 200-day MA of 555.21, indicating a bearish trend. The MACD of -2.06 indicates Positive momentum. The RSI at 46.15 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.

Perseus Proteomics, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
$2.24T12.0913.71%2.25%4.04%21.20%
75
Outperform
$1.35T35.314.61%2.28%3.62%-59.69%
68
Neutral
¥6.86T23.3118.32%1.63%14.09%31.96%
65
Neutral
$491.05B25.9810.94%26.28%
65
Neutral
¥352.42B10.85-2.99%2.46%11.67%-10.31%
56
Neutral
$26.12B-193.61%179.79%-204.13%
42
Neutral
¥6.00B
16.18%31.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4882
Perseus Proteomics, Inc.
407.00
-192.00
-32.05%
JP:4506
Sumitomo Dainippon Pharma Co
1,236.00
829.00
203.69%
JP:4151
Kyowa Kirin Co
2,584.50
-165.05
-6.00%
JP:4507
Shionogi & Co
2,547.00
647.39
34.08%
JP:4568
Daiichi Sankyo Company
3,678.00
-1,147.93
-23.79%
JP:4563
AnGes
74.00
24.00
48.00%

Perseus Proteomics, Inc. Corporate Events

Perseus Proteomics Releases FY2025 Business Forecasts Amid Licensing Challenges
Mar 31, 2025

Perseus Proteomics Inc. announced its business forecasts for the fiscal year ending March 31, 2025, with a focus on licensing agreements for its pipeline projects PPMX-T002 and PPMX-T003. The company anticipates significant R&D and administrative expenses, impacting its financial results. Despite challenges in forecasting due to incomplete licensing activities, Perseus Proteomics remains committed to maximizing the value of its projects, which could influence its market positioning and stakeholder interests.

Perseus Proteomics Completes Phase I Trial Report for PPMX-T003
Mar 18, 2025

Perseus Proteomics Inc. announced the completion of a clinical study report for its Phase I trial of PPMX-T003, an anti-transferrin receptor 1 antibody, in patients with polycythemia vera. The trial, which involved six subjects, demonstrated safety and indicated efficacy, with five subjects experiencing a 12-week period without the need for phlebotomy. The results have no impact on the company’s fiscal year 2025/3 business results.

Perseus Proteomics Updates PPMX-T003 Project Details
Feb 26, 2025

Perseus Proteomics Inc. has announced an amendment regarding its PPMX-T003 project, which is part of a drug discovery support program for orphan drugs. The amendment clarifies that the research group led by Dr. Ai Kotani at Osaka University, rather than Osaka Metropolitan University, has identified PPMX-T003 as a potential therapeutic drug for ANKL. This correction may impact stakeholders’ understanding of the project’s progress and the company’s collaboration with academic institutions.

Perseus Proteomics’ PPMX-T003 Gains Support for Orphan Drug Development
Feb 26, 2025

Perseus Proteomics Inc. announced that its drug candidate, PPMX-T003, intended for treating aggressive NK cell leukemia, has been selected for the Drug Discovery Support Program for Orphan drugs by Japan’s AMED. This selection supports the ongoing clinical trials, which have been extended by a year, and provides a subsidy of 100 million yen to aid in trial expenses, potentially impacting the company’s financial forecast for FY2026/3.

Perseus Proteomics Reports Financial Adjustments and Losses
Feb 14, 2025

Perseus Proteomics Inc. reported non-operating income, expenses, and extraordinary losses in the first nine months of the fiscal year ending March 2025. The company experienced gains from foreign exchange, outsourcing services, and interest, but also incurred costs related to capital increase and share issuance. A significant impairment loss on non-current assets was recorded, impacting the financial results for the third quarter, as announced.

Perseus Proteomics Reports Increased Sales but Continued Losses
Feb 14, 2025

Perseus Proteomics Inc. reported its financial results for the nine months ending December 31, 2024, showing a small increase in net sales by 15.9% compared to the previous year. Despite this, the company continues to experience financial losses, with a net loss recorded. The financial position showed an increase in total assets and net assets, but the company refrained from providing a forecast for the fiscal year ending March 31, 2025, citing difficulties in making rational predictions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025